LRAT — Lecithin Retinol Acyltransferase

The LRAT gene provides instructions for making an enzyme called lecithin retinol acyltransferase. This enzyme plays a crucial role in the eye, specifically in a process called the visual cycle. The visual cycle is how our eyes recycle vitamin A to create the light-sensitive molecules needed for vision. LRAT is responsible for the first step in this recycling process, converting vitamin A into a storage form within the cells that support the retina. When the LRAT gene is mutated, the enzyme does not work properly or is missing entirely. As a result, the eye cannot produce the light-sensitive molecules required for vision. This leads to a severe shortage of the necessary components for the light-detecting cells (photoreceptors) in the retina to function, causing these cells to gradually deteriorate and die. For patients and families, mutations in the LRAT gene cause severe vision problems that typically begin at birth or in early childhood. These conditions are often diagnosed as Leber congenital amaurosis (LCA) or early-onset severe retinal dystrophy. Symptoms include profound vision loss, night blindness, and involuntary eye movements (nystagmus). The condition is inherited in an autosomal recessive pattern, meaning a child must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry one mutated copy usually do not have any vision problems themselves.

Gene description: Encodes an enzyme crucial for vitamin A metabolism, converting retinol to retinyl esters for storage in the retinal pigment epithelium.

Patient and family guide: The LRAT gene provides instructions for making an enzyme called lecithin retinol acyltransferase. This enzyme plays a crucial role in the eye, specifically in a process called the visual cycle. The visual cycle is how our eyes recycle vitamin A to create the light-sensitive molecules needed for vision. LRAT is responsible for the first step in this recycling process, converting vitamin A into a storage form within the cells that support the retina. When the LRAT gene is mutated, the enzyme does not work properly or is missing entirely. As a result, the eye cannot produce the light-sensitive molecules required for vision. This leads to a severe shortage of the necessary components for the light-detecting cells (photoreceptors) in the retina to function, causing these cells to gradually deteriorate and die. For patients and families, mutations in the LRAT gene cause severe vision problems that typically begin at birth or in early childhood. These conditions are often diagnosed as Leber congenital amaurosis (LCA) or early-onset severe retinal dystrophy. Symptoms include profound vision loss, night blindness, and involuntary eye movements (nystagmus). The condition is inherited in an autosomal recessive pattern, meaning a child must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry one mutated copy usually do not have any vision problems themselves.

Gene function: LRAT is essential for the visual cycle, catalyzing the esterification of all-trans-retinol into all-trans-retinyl esters. This step is critical for storing vitamin A in the retinal pigment epithelium (RPE) and ensuring a continuous supply of 11-cis-retinal for photoreceptor function. Dysfunction leads to impaired chromophore regeneration and subsequent retinal degeneration.

Protein structure: The human LRAT gene encodes a protein of 230 amino acids with a calculated molecular mass of approximately 25.3 kDa. The LRAT protein belongs to the H-rev107 family of proteins and is an integral membrane protein. Structurally, the LRAT protein contains two putative transmembrane domains that anchor it to the membrane of the endoplasmic reticulum in the retinal pigment epithelium (RPE) and other tissues. It features a unique 30-amino acid insertion compared to other family members, which is thought to be important for its specific function. The catalytic activity relies on key residues, including a conserved cysteine (Cys161) and tyrosine (Tyr154), which are essential for accepting the acyl group from lecithin during the esterification process.

Molecular function: Lecithin retinol acyltransferase (LRAT) is a critical enzyme in the visual cycle, responsible for catalyzing the esterification of all-trans-retinol (vitamin A) into all-trans-retinyl esters within the retinal pigment epithelium (RPE). This reaction is the first step in the RPE visual cycle and is essential for the storage of retinoids and the subsequent generation of 11-cis-retinal, the light-sensitive chromophore required for both rod and cone opsins. LRAT transfers an acyl group from the sn-1 position of phosphatidylcholine (lecithin) to all-trans-retinol. The resulting all-trans-retinyl esters serve as the substrate for RPE65 (retinal pigment epithelium-specific 65 kDa protein), which converts them into 11-cis-retinol. Furthermore, LRAT acts as a molecular switch regulating the visual cycle by palmitoylating the membrane-associated form of RPE65, converting it to a soluble form and thereby modulating its chaperone activity and ligand binding selectivity based on the need for chromophore synthesis.

Expression pattern: The LRAT gene is predominantly expressed in tissues with high vitamin A processing activity. In the eye, it is highly expressed in the retinal pigment epithelium (RPE), where it plays a critical role in the visual cycle. Beyond the retina, LRAT is expressed at high levels in the liver (specifically in hepatic stellate cells, where it is involved in vitamin A storage), testis, small intestine, prostate, pancreas, and colon. It is also expressed at lower levels in the brain. This widespread expression pattern reflects its general role in retinoid metabolism and storage across different organ systems, although the most prominent clinical manifestations of LRAT deficiency are restricted to the visual system.

Mutation spectrum: The mutation spectrum of the LRAT gene includes a variety of loss-of-function variants, such as missense, nonsense, frameshift (small deletions or insertions), and splice-site mutations. These mutations are distributed across the gene and generally lead to a truncated or non-functional protein, completely abolishing its enzymatic activity. While LRAT mutations are a rare cause of inherited retinal diseases (accounting for less than 1% of Leber congenital amaurosis cases), certain founder mutations have been identified in specific populations. For example, a homozygous 2-bp deletion (c.217_218delAT) has been reported in patients of French and French-Canadian descent, and a c.12delC mutation is a common cause of LRAT-associated retinitis pigmentosa in the Dutch population.

Pathogenic variants: 1. p.Ser175Arg (c.525C>A) - A missense mutation that abolishes acyltransferase activity, associated with early-onset severe retinal dystrophy and juvenile retinitis pigmentosa. 2. c.217_218delAT (p.Tyr73fs) - A 2-bp deletion causing a frameshift and premature termination, identified as a potential founder mutation in French and French-Canadian populations with Leber congenital amaurosis. 3. c.12delC (p.Met5fs) - A frameshift mutation resulting in a heavily truncated protein, identified as a common cause of LRAT-associated retinitis pigmentosa in the Dutch population. 4. c.396_397delAA (p.Lys133fs) - A 2-bp deletion leading to a frameshift and premature stop codon, associated with severe early-onset retinal dystrophy.

Clinical significance: Mutations in the LRAT gene are primarily associated with early-onset severe retinal dystrophy (EOSRD) and Leber congenital amaurosis 14 (LCA14), both of which are autosomal recessive inherited retinal diseases. Patients typically present with severe vision loss or blindness from birth or early infancy, accompanied by nystagmus, sluggish pupillary responses, and severely attenuated or non-detectable electroretinogram (ERG) responses. The clinical spectrum can also include juvenile retinitis pigmentosa (RP) and retinitis punctata albescens, characterized by night blindness (nyctalopia) in early childhood, progressive visual field constriction, and eventual central vision loss. Funduscopic examination often reveals optic disc pallor, attenuated retinal arterioles, peripheral retinal pigment epithelium (RPE) atrophy, and macular changes, though typical bone-spicule pigmentation may be sparse early in the disease course. The severity and progression rate can vary, but the visual prognosis is generally poor without intervention.

Inheritance: Autosomal Recessive

Chromosomal location: 4q32.1

Genotype-phenotype correlations: Genotype-phenotype correlations for LRAT mutations are generally consistent with the severe disruption of the visual cycle. Most identified pathogenic variants, including frameshifts, nonsense mutations, and essential splice-site alterations, result in a complete loss of functional LRAT protein. This profound deficiency leads to the severe, early-onset phenotypes of Leber congenital amaurosis (LCA) and early-onset severe retinal dystrophy (EOSRD). Some missense mutations, such as p.Ser175Arg, have been shown in vitro to completely abolish acyltransferase activity, correlating with the severe clinical presentation seen in patients homozygous for this variant. While the clinical diagnosis may vary slightly (e.g., LCA vs. juvenile retinitis pigmentosa) depending on the age of presentation and specific clinical criteria used, the underlying mechanism of severe chromophore deprivation consistently results in early and progressive photoreceptor degeneration.

Research and therapeutic approaches: Currently, there are no FDA-approved therapies specifically for LRAT-associated inherited retinal diseases. However, because LRAT and RPE65 function in the same biochemical pathway (the visual cycle), therapeutic strategies developed for RPE65 deficiency are being actively explored for LRAT deficiency. One major approach is oral retinoid replacement therapy using artificial chromophores, such as 9-cis-retinyl acetate (e.g., QLT091001), which bypass the need for LRAT and RPE65 by directly providing a functional analog of 11-cis-retinal to the photoreceptors. Clinical trials have shown some promise in improving visual fields and visual acuity in patients with LRAT or RPE65 mutations. Gene replacement therapy is another highly promising avenue. Similar to the successful development of Luxturna (voretigene neparvovec-rzyl) for RPE65-associated LCA, researchers are developing adeno-associated virus (AAV) vectors to deliver a functional copy of the LRAT gene to the retinal pigment epithelium. Preclinical studies in Lrat knockout animal models have demonstrated that subretinal injection of AAV-LRAT can restore visual function and preserve retinal structure. While LRAT gene therapy has not yet reached the advanced clinical trial stages of RPE65 therapies, proof-of-concept studies strongly support its potential as a future treatment option.

Diagnostic testing: Diagnostic testing for LRAT-associated inherited retinal diseases typically involves comprehensive genetic testing, as the clinical presentation overlaps significantly with other forms of Leber congenital amaurosis (LCA) and early-onset retinitis pigmentosa (RP). Multigene panel testing for inherited retinal dystrophies or whole exome sequencing (WES) are the preferred methods to identify biallelic pathogenic variants in the LRAT gene. Genetic counseling is essential for affected individuals and their families. Since LRAT mutations are inherited in an autosomal recessive manner, parents of an affected child are obligate carriers, and each subsequent pregnancy carries a 25% risk of being affected. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.

Animal models: The most widely used animal models for studying LRAT function are Lrat knockout (Lrat-/-) mice and rats. These models exhibit early-onset, severe retinal degeneration due to the inability to synthesize 11-cis-retinal, mimicking the human Leber congenital amaurosis (LCA) phenotype. In Lrat-/- mice, rod and cone photoreceptors undergo progressive degeneration, with cone loss being particularly rapid and severe. A recently developed Lrat-/- rat model (created via CRISPR/Cas9 with a c.12delA mutation homologous to a human founder mutation) also shows significant retinal thinning and loss of visual function. These models have been crucial for testing therapeutic interventions, demonstrating that early administration of artificial chromophores (like 9-cis-retinyl acetate) or gene replacement therapy can partially rescue photoreceptor survival and restore visual responses.

Population genetics: Mutations in the LRAT gene are a very rare cause of inherited retinal diseases globally. However, specific founder mutations have been identified in certain populations, leading to a higher local prevalence. For instance, the c.217_218delAT mutation has been observed in individuals of French and French-Canadian descent, suggesting a founder effect. Similarly, the c.12delC mutation is a notable cause of LRAT-associated retinitis pigmentosa in the Dutch population. Overall carrier frequencies in the general population are extremely low, consistent with the rarity of LRAT-associated Leber congenital amaurosis and early-onset severe retinal dystrophy.

Selected references: 1. Ruiz A, et al. Molecular and biochemical characterization of lecithin retinol acyltransferase. J Biol Chem. 1999. PMID: 9920938 2. Thompson DA, et al. Mutations in the gene encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy. Nat Genet. 2001. PMID: 11381255 3. Xue L, et al. A palmitoylation switch mechanism in the regulation of the visual cycle. Cell. 2004. PMID: 15186777 4. Senechal A, et al. Screening genes of the retinoid metabolism: novel LRAT mutation in Leber congenital amaurosis. Am J Ophthalmol. 2006. PMID: 17011878 5. Maeda T, et al. Loss of cone photoreceptors caused by chromophore depletion is partially prevented by the artificial chromophore pro-drug, 9-cis-retinyl acetate. Hum Mol Genet. 2009. PMID: 19339306 6. Koster C, et al. The Lrat-/- rat: CRISPR/Cas9 construction and phenotyping of a new animal model for retinitis pigmentosa. Int J Mol Sci. 2021. PMID: 34299053 7. Borman AD, et al. Early-onset retinal dystrophy due to mutations in LRAT: molecular analysis and detailed phenotypic study. Invest Ophthalmol Vis Sci. 2012. PMID: 22589432